An Exploratory Evaluation of the Tau Protein Binding Properties, Whole-Body Biodistribution and Safety of 18F-AV-1451 Injection in Healthy Volunteers and Cognitively Impaired Subjects
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Flortaucipir-F-18 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; Diagnostic use
- Sponsors Avid Radiopharmaceuticals
- 20 Jul 2020 New trial record